Accent Therapeutics, Inc.

We express our deep and enduring gratitude to Robert Copeland for his leadership and foundational contributions to Accent! #oncology #cancerresearch #drugdevelopment

Please join us in congratulating Serena Silver, Ph.D. in her appointment as Accent’s CSO, effective January 1, 2025! Dr. Silver joined Accent in September 2022 as Vice President of Biology, bringing a breadth of experience across target discovery, drug discovery, and translational research. We are grateful for her ongoing leadership as we enter clinical development. #oncology #cancerresearch #drugdevelopment

📢 NEWS: The first patient has been dosed in Accent’s Phase 1/2 trial of ATX-559, our first-in-class oral DHX9 inhibitor! Learn more: https://bit.ly/41nQrkR #cancerresearch #drugdevelopment #DHX9 #clinicaltrial #breastcancer #colorectalcancer

If attending the RNA-Targeted Drug Discovery & Development Summit in Boston this week, be sure to prioritize Dr. Kenny Duncan's seminar on Wednesday, December 11th. He will be presenting Accent's development of DHX9 inhibitors for MSI-high and BRCA-deficient cancers as well as discovery of allosteric inhibitors of XRN1. #AccentTherapeutics #DrugDiscovery #DHX9 #XRN1 #Kenneth Duncan https://lnkd.in/ex7kz3zS

Accent is thrilled to announce the publication of the research validating the RNA and DNA/RNA hybrid helicase DHX9 as a target for microsatellite-instable high (MSI-H) tumors with defective mismatch repair (dMMR) in the journal Cancer Research, as well as the identification of the tool compound, ATX968.  This groundbreaking study is the first report detailing the in vivo efficacy of a DHX9 inhibitor, providing proof of concept for inhibition of DHX9 enzymatic activity as a potential therapeutic in select cancers.    This work was made possible through the hard work and collaborative efforts of our dedicated research team and CRO partners.   We are immensely proud of this achievement and look forward to the positive impact it will have on the scientific community and future therapeutic developments.   #DHX9 #CancerResearch #ChemicalBiology #AccentTherapeutics   Read the full paper here: https://lnkd.in/ewg8Uk9x  

Accent is well represented at the AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer, held in Bellevue, Washington! Serena Silver, Head of Biology, will present data on Accent’s lead program,, the RNA helicase DHX9. Ann Boriack-Sjodin, Head of Molecular Discovery, will share insights on our early-stage efforts on the RNA exoribonuclease XRN1. Dr. Howard Chang of Stanford University, and co-founder of Accent, is a key conference organizer. Thank you to our incredible team for representing Accent and exemplifying our core values of Patient Focus, Contagious Enthusiasm, and Rigor^2! #CancerResearch #AACR #RNA #DHX9 #XRN1 #AccentTherapeutics https://lnkd.in/giwqY-qd

Please join us in welcoming Lillian Siu, MD, FRCPC, Josep Tabernero MD, PhD, and Samuel Blackman, MD, PhD, to our Clinical Advisory Board! This esteemed group of clinician-scientists and leaders in oncology drug development will provide invaluable insights and clinical expertise as we advance our programs and work to bring transformative therapies to patients. #oncology #cancerresearch #drugdevelopment

📢 NEWS: The FDA has cleared our Investigational New Drug (IND) application for ATX-559, our first-in-class oral DHX9 inhibitor, paving the way for a Phase 1/2 trial focused on patients with BRCA1/2-deficient breast cancer and solid tumors with microsatellite instability and/or deficient mismatch repair (NCT06625515). Learn more: https://bit.ly/40bAbmq #cancerresearch #drugdevelopment #DHX9 #clinicaltrial #breastcancer #colorectalcancer

Thank you, Ann Boriack-Sjodin for representing Accent! We were happy to host the event.

Congratulations to Howard Chang, MD, PhD of Stanford University, an Accent Founder and recipient of the 2024 Albany Medical Center Prize in Medicine and Biomedical Research for his research on RNA-mediated gene regulation. Accent is celebrating with you, Howard! https://lnkd.in/eq29z_Ky